Full-Time

Senior Financial Analyst

R&D & Medical Affairs

Confirmed live in the last 24 hours

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Biotechnology
Healthcare

Compensation Overview

$95.1k - $138.1kAnnually

+ Annual Bonus + Equity Incentive Program

Senior

San Diego, CA, USA

Category
Financial Planning and Analysis (FP&A)
Medical, Clinical & Veterinary
Finance & Banking
Required Skills
Financial analysis
Excel/Numbers/Sheets
Financial Modeling

You match the following Neurocrine Biosciences's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • BS/BA degree in Finance, Business Administration, Accounting or closely related field and 6+ years of financial analysis experience; Pharmaceutical and/or Biotech industry experience is a plus Experience as client-facing finance resource is preferred. Financial system experience is preferred OR
  • Master’s degree or MBA and 4+ years of similar experience noted above
  • Understands key business drivers and uses this understanding to accomplish work
  • Has strong understanding of processes, procedures and systems used to accomplish the work and recognizes downstream impact on other functional areas
  • Proficient with tools and processes that support work conducted by functional area
  • Ability to work as part of a team
  • Interested in R&D, drug development and making an impact on patients’ lives
  • Has knowledge of best practices in Finance and Accounting and familiarity with the broader underlying concepts of related business disciplines
  • Experience in Life Sciences, Biotechnology, or pharmaceutical industry preferred
  • R&D and/or drug development Finance experience a plus
  • Excellent computer skills
  • Strong communications, problem-solving, analytical thinking skills
  • Detail oriented yet can see broader picture for department
  • Ability to meet multiple deadlines, with a high degree of accuracy and efficiency
  • Strong project management skills
  • Demonstrated ability to effectively collaborate with a diverse set of stakeholders
  • Strong analytical and mathematical skills
  • Strong knowledge of MS Excel or other financial modeling tools or software
  • Working knowledge of financial planning and control processes, policies
  • Good knowledge of GAAP and Accounting guidelines preferred
  • Demonstrated hands-on knowledge of monthly, quarterly and annual close process
  • Strong financial analysis skills, framing of complex financial issues, and supporting strategic decisions
  • Ability to clearly and concisely explain complex issues, financial or otherwise
  • Strong interest in client-facing financial role and 'embedded' within a function(s)
Responsibilities
  • Acts as a key partner in supporting the assigned functions and programs in financial and business planning analysis, reporting, and operations
  • Creates and/or updates financial models that support decision-making and provide valuable insight to Senior Leaders and project teams
  • Reviews and analyzes monthly, quarterly, and annual results, helping to understand variances of actuals vs budget or forecast
  • Analyzes departmental budgets and plays a key role in forecasting efforts to support financial planning and overall guidance
  • Collaborates with cross-functional business partners and teams within assigned functions and Accounting
  • Identifies and delivers opportunities to simplify and improve processes and systems and create operational efficiencies
  • Performs ad-hoc analyses that lead to problem solving, decision-making, and actionable recommendations for the business
  • Collects and analyzes financial information for assigned business in order to track the organization's progress against financial goals
  • Other duties as assigned
Desired Qualifications
  • Experience in Life Sciences, Biotechnology, or pharmaceutical industry preferred
  • R&D and/or drug development Finance experience a plus
  • Good knowledge of GAAP and Accounting guidelines preferred
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

N/A

Headquarters

San Diego, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • CRENESSITY launch positions Neurocrine as a leader in niche markets with high unmet needs.
  • $500 million share repurchase indicates strong financial health and growth confidence.
  • Collaboration with Nxera Pharma could lead to innovative treatments for schizophrenia and dementia.

What critics are saying

  • Increased competition in neuropsychiatric drugs may impact Neurocrine's market share.
  • Potential delays in osavampator's Phase 3 program could affect market entry timeline.
  • Dependence on CRENESSITY's success in the U.S. market poses sales and reputation risks.

What makes Neurocrine Biosciences unique

  • Neurocrine focuses on first-in-class treatments for rare disorders like CAH.
  • Strategic collaboration with Takeda enhances Neurocrine's psychiatric disorder portfolio.
  • Partnership with PANTHERx Rare ensures specialized support for CRENESSITY distribution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Parental Leave

Health Insurance

Dental Insurance

Vision Insurance

Paid Holidays

Company News

PR Newswire
Feb 21st, 2025
Neurocrine Biosciences Board Of Directors Authorizes $500 Million Share Repurchase Program

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.William Rastetter, Chairman of the Board of Directors of Neurocrine Biosciences, said, "This authorization reflects our approach to capital allocation that balances driving sustained revenue growth through investing in our commercial products, INGREZZA and CRENESSITY, advancing our expanding R&D pipeline and returning capital to shareholders."Under the new authorization, repurchases may be made from time to time at management's discretion through a variety of methods, such as open-market transactions including pre-set trading plans, privately negotiated transactions, accelerated share repurchases, and other transactions in accordance with applicable securities laws.About Neurocrine BiosciencesNeurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life- changing treatments for patients with under-addressed neuropsychiatric, neurological, and neuroendocrine disorders. The company's diverse portfolio includes U.S

PR Newswire
Jan 27th, 2025
Neurocrine Biosciences Announces Amendment To Strategic Collaboration With Takeda To Develop And Commercialize Osavampator (Formerly Nbi-1065845/Tak-653)

- Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator- Takeda Reacquires Rights to Osavampator in JapanSAN DIEGO, Jan. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder (MDD) in all territories worldwide except Japan, where Takeda will reacquire exclusive rights. Under the terms of the updated agreement, each company is responsible for development costs in their respective region, and both companies are eligible to receive royalty payments."This streamlined collaboration structure allows Neurocrine to focus on bringing this important medicine to patients as quickly as possible," said Kyle Gano, Ph.D., Chief Executive Officer at Neurocrine Biosciences. "With the recent successful completion of our End-of-Phase 2 meeting with FDA for osavampator, we look forward to beginning the Phase 3 program in the first half of this year.""With its long-standing expertise developing therapies for serious psychiatric disorders, Neurocrine is the ideal partner to develop osavampator," said Sarah Sheikh, M.Sc., B.M., B.Ch, MRCP, Head, Neuroscience Therapeutic Area Unit and Head, Global Development at Takeda

PR Newswire
Jan 21st, 2025
Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today In The Journal Of Clinical Endocrinology Metabolism

SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM), sponsored by the company. The supplement, titled "Challenges and Opportunities in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Throughout the Lifetime," contains eight review articles that provide a comprehensive look at the clinical, psychosocial, treatment-related and day-to-day challenges faced by individuals with classic CAH. JCEM is a leader in disseminating research that supports healthcare providers, patients and caregivers in advancing the understanding and management of various endocrinology conditions, such as CAH."Our understanding of the genetics, pathophysiology, and complications of CAH has exploded over the last 20 years," said Dr. Richard Auchus, M.D., Ph.D., Principal Investigator, Professor of Pharmacology and Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes at the University of Michigan

ForexTV
Jan 14th, 2025
Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio

Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Nxera for the treatment of schizophrenia, dementia and other neuropsychiatric disorders.

PR Newswire
Jan 6th, 2025
Neurocrine Biosciences To Present At The 43Rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 43rd Annual J.P. Morgan Healthcare Conference at 8:15 a.m. Pacific Time on Monday January 13, 2025 in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference.The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com